Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Whitney, Gladney"'
Autor:
Whitney Gladney, Adina Vultur, Michael Schweizer, Joseph Fraietta, Andrew Rech, Carl June, Matthew O’Rourke, Amy Roberts, Hinel Patel, Jamie Rosen, Pam Hufner, Yanping Luo, David Barrett, Thomas Fountaine, Karen Chagin
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fd7c312c2cb00806d8e29d95d093808
https://doi.org/10.1136/jitc-2022-sitc2022.0335
https://doi.org/10.1136/jitc-2022-sitc2022.0335
Autor:
Vivek, Narayan, Julie S, Barber-Rotenberg, In-Young, Jung, Simon F, Lacey, Andrew J, Rech, Megan M, Davis, Wei-Ting, Hwang, Priti, Lal, Erica L, Carpenter, Shannon L, Maude, Gabriela, Plesa, Neha, Vapiwala, Anne, Chew, Michael, Moniak, Ronnie A, Sebro, Michael D, Farwell, Amy, Marshall, Joan, Gilmore, Lester, Lledo, Karen, Dengel, Sarah E, Church, Tyler D, Hether, Jun, Xu, Mercy, Gohil, Thomas H, Buckingham, Stephanie S, Yee, Vanessa E, Gonzalez, Irina, Kulikovskaya, Fang, Chen, Lifeng, Tian, Kyle, Tien, Whitney, Gladney, Christopher L, Nobles, Hayley E, Raymond, Elizabeth O, Hexner, Donald L, Siegel, Frederic D, Bushman, Carl H, June, Joseph A, Fraietta, Bruce L, Levine
Publikováno v:
Nature medicine. 28(4)
Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the immunosuppressive tumor microenvironment (TME), characterized by high l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a7bb7fa879c20cb8e11ab244db1c24b2
https://pubmed.ncbi.nlm.nih.gov/35411068
https://pubmed.ncbi.nlm.nih.gov/35411068
Autor:
David Barrett, Karen Chagin, Thomas J. Fountaine, Andrea Moore, Mignane Ka, Whitney Gladney, Bhavna Verma, Yanping Luo, Daniel Hui, Vijay Gopal Reddy Peddareddigari
Publikováno v:
Journal of Clinical Oncology. 40:158-158
158 Background: Early clinical responses to anti-PSMA Chimeric Antigen Receptor T cells (CARs) have been observed but much like the leukemia experience, significant toxicity from macrophage activation (MAS) has also been observed Building on our expe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c79fef99a3c2df258c1e81316c1fec35
https://doi.org/10.1200/jco.2022.40.6_suppl.158
https://doi.org/10.1200/jco.2022.40.6_suppl.158
Autor:
Meredith McKean, Matthew H. Carabasi, Mark N. Stein, Michael Thomas Schweizer, Jason J. Luke, Vivek Narayan, Rahul Atul Parikh, Russell Kent Pachynski, Jingsong Zhang, Vijay Gopal Reddy Peddareddigari, James Winnberg, Amy Roberts, Jamie Rosen, Pam Hufner, Whitney Gladney, Thomas J. Fountaine, Karen Chagin
Publikováno v:
Journal of Clinical Oncology. 40:94-94
94 Background: CART-PSMA-02 is a multi-center, open-label, phase 1 trial evaluating the safety and feasibility of CART-PSMA-TGFβRDN T-cells (PSMA-CART) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). PSMA-CART are eng
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf5e7c4867c45aa22e0ef8e0fbd862f2
https://doi.org/10.1200/jco.2022.40.6_suppl.094
https://doi.org/10.1200/jco.2022.40.6_suppl.094